Arginine deprivation therapy for malignant melanoma

Jung-Ki Yoon,1,2 Arthur E Frankel,3 Lynn G Feun,4 Suhendan Ekmekcioglu,1 Kevin B Kim11Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;&nbsp;2Hwasung Public Health Center, Hwasung, South Korea, 3Scott and White Cancer Research Insti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/b086f0e339804ad6bd801034248563f2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b086f0e339804ad6bd801034248563f2
record_format	dspace
spelling	oai:doaj.org-article:b086f0e339804ad6bd801034248563f22021-12-02T02:30:24ZArginine deprivation therapy for malignant melanoma1179-1438https://doaj.org/article/b086f0e339804ad6bd801034248563f22012-12-01T00:00:00Zhttp://www.dovepress.com/arginine-deprivation-therapy-for-malignant-melanoma-a11816https://doaj.org/toc/1179-1438Jung-Ki Yoon,1,2 Arthur E Frankel,3 Lynn G Feun,4 Suhendan Ekmekcioglu,1 Kevin B Kim11Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;&nbsp;2Hwasung Public Health Center, Hwasung, South Korea, 3Scott and White Cancer Research Institute, Temple, TX, USA;&nbsp;4Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USAAbstract: Despite recent development of promising immunotherapeutic and targeted drugs, prognosis in patients with advanced melanoma remains poor, and a cure for this disease remains elusive in most patients. The success of melanoma therapy depends on a better understanding of the biology of melanoma and development of drugs that effectively target the relevant genes or proteins essential for tumor cell survival. Melanoma cells frequently lack argininosuccinate synthetase, an essential enzyme for arginine synthesis, and as a result they become dependent on the availability of exogenous arginine. Accordingly, a therapeutic approach involving depletion of available arginine has been shown to be effective in preclinical studies. Early clinical studies have demonstrated sufficient antitumor activity to give rise to cautious optimism. In this article, the rationale for arginine deprivation therapy is discussed. Additionally, various strategies for depleting arginine are discussed and the preclinical and clinical investigations of arginine deprivation therapy in melanoma are reviewed.Keywords: arginine deprivation, argininosuccinate synthetase, melanomaYoon JKFrankel AEFeun LGEkmekcioglu SKim KBDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss default, Pp 11-19 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Yoon JK Frankel AE Feun LG Ekmekcioglu S Kim KB Arginine deprivation therapy for malignant melanoma
description	Jung-Ki Yoon,1,2 Arthur E Frankel,3 Lynn G Feun,4 Suhendan Ekmekcioglu,1 Kevin B Kim11Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;&nbsp;2Hwasung Public Health Center, Hwasung, South Korea, 3Scott and White Cancer Research Institute, Temple, TX, USA;&nbsp;4Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USAAbstract: Despite recent development of promising immunotherapeutic and targeted drugs, prognosis in patients with advanced melanoma remains poor, and a cure for this disease remains elusive in most patients. The success of melanoma therapy depends on a better understanding of the biology of melanoma and development of drugs that effectively target the relevant genes or proteins essential for tumor cell survival. Melanoma cells frequently lack argininosuccinate synthetase, an essential enzyme for arginine synthesis, and as a result they become dependent on the availability of exogenous arginine. Accordingly, a therapeutic approach involving depletion of available arginine has been shown to be effective in preclinical studies. Early clinical studies have demonstrated sufficient antitumor activity to give rise to cautious optimism. In this article, the rationale for arginine deprivation therapy is discussed. Additionally, various strategies for depleting arginine are discussed and the preclinical and clinical investigations of arginine deprivation therapy in melanoma are reviewed.Keywords: arginine deprivation, argininosuccinate synthetase, melanoma
format	article
author	Yoon JK Frankel AE Feun LG Ekmekcioglu S Kim KB
author_facet	Yoon JK Frankel AE Feun LG Ekmekcioglu S Kim KB
author_sort	Yoon JK
title	Arginine deprivation therapy for malignant melanoma
title_short	Arginine deprivation therapy for malignant melanoma
title_full	Arginine deprivation therapy for malignant melanoma
title_fullStr	Arginine deprivation therapy for malignant melanoma
title_full_unstemmed	Arginine deprivation therapy for malignant melanoma
title_sort	arginine deprivation therapy for malignant melanoma
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/b086f0e339804ad6bd801034248563f2
work_keys_str_mv	AT yoonjk argininedeprivationtherapyformalignantmelanoma AT frankelae argininedeprivationtherapyformalignantmelanoma AT feunlg argininedeprivationtherapyformalignantmelanoma AT ekmekcioglus argininedeprivationtherapyformalignantmelanoma AT kimkb argininedeprivationtherapyformalignantmelanoma
_version_	1718402432487129088

Arginine deprivation therapy for malignant melanoma

Ejemplares similares